Avadel Pharmaceuticals plc - ADR

NASDAQ:AVDL  
2.32
-0.11 (-4.53%)
Products

Avadel Pharmaceuticals Says On May 24, 2022, Co Received Proposed, Final Label And Medication Guide For Ft218 From FDA

Published: 05/26/2022 11:27 GMT
Avadel Pharmaceuticals plc - ADR (AVDL) - Avadel Pharmaceuticals - on May 24, 2022, Co Received Proposed, Final Label and Medication Guide for Ft218 From FDA.
Avadel Pharmaceuticals- Was Notified by FDA That Ft218 NDA Patent Statement Pertaining to US Patent No. 8,731,963 Was Deemed Inappropriate by FDA.
Avadel Pharmaceuticals - FDA Has Requested the Company Add a Certification to the Rems Patent to Its NDA.
Avadel Pharmaceuticals-anticipates Tentative Approval of Ft218 NDA With Potential Full Approval on Or Before Expiration of Rems Patent on June 17,2023.